Our editorial team dives into the pharma industry's reaction to US tariffs on imports from the European Union and major trends from Q2 earnings calls.

PharmaTher's ketamine product is the first to be approved in an analgesic setting by the FDA, offering competition to opiates moving forward.

Fosun Pharma Industrial has entered a licence agreement to grant ex-China rights for its respiratory drug, XH-S004, to Expedition.

South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

Sartorius has agreed to invest $3m in Nanotein Technologies, engaged in the development of advanced immune cell activation reagents.

Vinay Prasad resumes leadership at the FDA’s CBER two weeks after he resigned amid cell and gene therapy controversy.

Biostar Stem Cell Technology Research Institute has received Japan's MHLW approval for its angel stem cell therapy for ASD.

A new pill that combats antibiotic-resistant strains of gonorrhoea is closer to US approval, after the FDA accepted GSK’s gepotidacin for priority review.

This will be the first time the option has been taken up since it was introduced at the beginning of 2025, under the Medical Research Act.

WeightWatchers is now only offering Wegovy while other telehealth providers defiantly hang on to compounded alternatives.

Linked data could unlock essential hidden insights across healthcare – but linking has to be executed correctly to avoid ...

Europe’s cannabis pharmaceutical sector is shifting as scientific rigour, regulatory clarity and cautious capital define its next chapter.